OncoLens Raises Seed Funding To Streamline Cancer Treatment Planning
Holly Beilin ; Hypepotamus.com
March 26, 2019
(Atlanta) OncoLens, a clinical decision software that focuses on oncology (cancer care), has closed a $1.35 million seed round led by BIP Capital and Atlanta Technology Angels (ATA).
The platform aggregates that clinical history, any imaging the patients has had, data on available clinical trials they might benefit from, the most recent relevant research, and national quality metrics. When the board sits down to discuss the case, they already have a bevy of research and treatment options in front of them.
Once the group decides on a treatment plan, the platform sends out specific directives to each member of the care team.
“There’s a very easy way to disseminate this, not just to the original physician, but to every member of the care team,” says Mathew. That could include pathologists, radiologists, oncologists, even nutritionists.
The startup already counts several health systems and cancer centers as clients, and in 2018 was used for more than 800 tumor boards evaluating an even greater number of cases. It not only provides better data, says Mathew, but saves a great deal of time, which in medicine can translate to more lives saved.
The seed funding will largely go toward expanding the national footprint of the Atlanta-based startup, enabling them to get their software into more health systems and cancer centers across the country.